November 7, 2017, Vol 318, No. 17, Pages 1625-1728
Targeting Immune Checkpoints in Cancer Therapy
Suzanne L. Topalian, MD
JAMA. 2017;318(17):1647-1648. doi:10.1001/jama.2017.14155
This Viewpoint reviews the development of immune checkpoint inhibitors as a new drug class for treating cancer, and discusses future directions including development of commercial assays for identifying response-to-treatment biomarkers and the use of combination regimens to improve response.
Vaccination Challenges in Confronting the Resurgent Threat From Yellow Fever
Lin H. Chen, MD; Davidson H. Hamer, MD
JAMA. 2017;318(17):1651-1652. doi:10.1001/jama.2017.14258
This Viewpoint examines strategies for vaccinating travelers against yellow fever given recent vaccine shortages and global yellow fever outbreaks.